Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements Of Cash Flows

v2.4.0.6
Condensed Consolidated Statements Of Cash Flows (USD $)
In Thousands, unless otherwise specified
 3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Cash flows from operating activities:    
Net loss $ (115,533) $ (8,330)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 23 88
Stock-based compensation expense 398 249
Change in common stock warrant value 108,391 939
Changes in operating assets and liabilities:    
Collaboration receivable (37,540)  
Prepaid expenses and other assets (223) 2
Accounts payable (1,082) 352
Accrued clinical and development expenses 238 258
Accrued liabilities 279 508
Deferred rent 109 (71)
Deferred revenue 57,248  
Net cash provided by (used in) operating activities 12,308 (6,005)
Cash flows from investing activities:    
Acquisition of property and equipment (34)  
Acquisition of marketable securities (17,940) (5,744)
Proceeds from sales and maturities of marketable securities 8,492 3,285
Net cash used in investing activities (9,482) (2,459)
Cash flows from financing activities:    
Proceeds from issuance of common stock and warrants, net of offering expenses 17,227 29,692
Net cash provided by financing activities 17,227 29,692
Net increase in cash and cash equivalents 20,053 21,228
Cash and cash equivalents, beginning of period 5,882 8,691
Cash and cash equivalents, end of period 25,935 29,919
Supplemental schedule of non-cash investing and financing activities    
Change in unrealized gain (loss) on marketable securities $ 2 $ (4)